Evidence map›Paper›PMID 36902232›Full record

ReviewInternational journal of molecular sciences2023

Halloysite Nanotubes and Sepiolite for Health Applications.

Giuseppa Biddeci, Gaetano Spinelli, Paolo Colomba, Francesco Di Blasi

Full text readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giuseppa BiddeciInstitute for Innovation and Biomedical Research (IRIB), CNR, 90146 Palermo, Italy.
Gaetano SpinelliInstitute for Innovation and Biomedical Research (IRIB), CNR, 90146 Palermo, Italy.
Paolo ColombaInstitute for Innovation and Biomedical Research (IRIB), CNR, 90146 Palermo, Italy.ORCID 0000-0002-2470-7030
Francesco Di BlasiInstitute for Innovation and Biomedical Research (IRIB), CNR, 90146 Palermo, Italy.ORCID 0000-0001-8085-7538

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The need for safe, therapeutically effective, and patient-compliant drug delivery systems continuously leads researchers to design novel tools and strategies. Clay minerals are widely used in drug products both as excipients and active agents but, in recent years, there has been a growing interest in research aimed at the development of new organic or inorganic nanocomposites. The attention of the scientific community has been drawn by nanoclays, thanks to their natural origin, worldwide abundance, availability, sustainability, and biocompatibility. In this review, we focused our attention on the studies inherent to the pharmaceutical and biomedical applications of halloysite and sepiolite, and their semi-synthetic or synthetic derivatives, as drug delivery systems. After having described the structure of both materials and their biocompatibility, we delineate the use of the nanoclays to enhance the stability, the controlled release, the bioavailability, and the adsorption properties of drugs. Several types of surface functionalization have been discussed, showing that these materials could be used for the development of an innovative therapeutic approach.

Indexed as

Drug Delivery SystemsNanotubesClayHumansMagnesium SilicatesPharmaceutical PreparationsClayMagnesium Silicatesmagnesium trisilicatePharmaceutical Preparationsbiomedical applicationclay mineralsdrug deliveryhalloysitenanomaterialssepiolite

Identifiers

PMID36902232
PMCPMC10003602

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read44
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.